(20 [19] years) and all had neuropathy. Three out of 24 patients developed infection (two superficial and one deep) and one had a postoperative bleeding. Less frequent pain among the patients were reported from one center. About one third or more of the patients still complained of pain, mostly mild, in the biopsy area and paraesthesia in the foot two years after surgery. More than two third of the patients were reluctant to a further biopsy; a crucial information in drug trial planning. Conclusions: Sequelae of a sural nerve biopsy occur in type 1 diabetes. Risk for wound infections should be considered.

No abstract